# US 2023/0272479 A1 · Biomarker based patient selection for proteasome inhibitor treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0272479 A1
- Document ID: US20230272479A1
- Status: Published application
- Kind: A1
- Application number: 18/010,580
- Filed: 2021-06-17
- Published: 2023-08-31
- Earliest claimed: 2020-06-17
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Jacob M. Winter; Jared Rutter
- Web page: https://patentgrep.com/patent/US20230272479A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57595: {involving intracellular compounds}
- A61K 31/69: Boron compounds
- A61K 38/05: Dipeptides
- A61K 38/07: Tetrapeptides
- A61P 35/00: Antineoplastic agents
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- G01N 2333/916: acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are any of the methods or compositions herein. Disclosed are methods of treating a subject having cancer comprising administering a proteasome inhibitor to the subject having cancer, wherein the subject having cancer has a non-functional ATAD1 gene. Disclosed are methods of diagnosing and treating cancer, the method comprising: diagnosing a subject as being susceptible to treatment by a proteasome inhibitor; and administering a proteasome inhibitor to the subject.

## Claims

### Claim 1

A method of treating a subject having cancer comprising administering a proteasome inhibitor to the subject having cancer, wherein the subject having cancer has a non-functional ATAD1 gene.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject further comprises a non-functional PTEN genes.

### Claim 3

The method of any of the preceding claims, wherein a portion or all of the ATAD1 gene is deleted.

### Claim 4

The method of any of the preceding claims, wherein a portion of all of the PTEN gene is deleted.

### Claim 5

The method of any of the preceding claims, wherein the subject has breast cancer, lung cancer, colon cancer, brain cancer, or prostate cancer.

### Claim 6

A method of diagnosing and treating cancer in a subject, the method comprising:
a) diagnosing a subject as being susceptible to treatment by a proteasome inhibitor; and
b) administering a proteasome inhibitor to the subject.

### Claim 7 (depends on 6)

The method of claim 6, wherein diagnosing the subject as being susceptible to treatment by a proteasome inhibitor comprises identifying the subject as having a non-functional ATAD1 gene.

### Claim 8 (depends on 7)

The method of claim 7, wherein diagnosing the subject as being susceptible to treatment by a proteasome inhibitor further comprises identifying the subject as having a non-functional PTEN gene.

### Claim 9 (depends on 6, 7, 8)

The method of any one of claims 6-8, wherein diagnosing the subject as being susceptible to treatment by a proteasome inhibitor further comprises detecting an increase in BIM levels.

### Claim 10 (depends on 9)

The method of claim 9, wherein an increase in BIM levels is an increase compared to a standard.

### Claim 11

The method of any of the preceding claims, wherein subject having a non-functional ATAD1 gene is a subject having a portion of all of the ATAD1 gene deleted.

### Claim 12

The method of any of the preceding claims, wherein subject having a non-functional PTEN gene is a subject having a portion of all of the PTEN gene deleted.

### Claim 13 (depends on 6, 7, 8, 9, 10, 11, 12)

The method of any of claims 6-12, wherein the subject has breast cancer, lung cancer, colon cancer, brain cancer, or prostate cancer.

### Claim 14

A method of increasing apoptosis in a subject comprising administering a proteasome inhibitor to the subject, wherein the subject comprises a non-functional ATAD1 gene.

### Claim 15 (depends on 14)

The method of claim 14, wherein the subject further comprises a non-functional PTEN gene.

### Claim 16 (depends on 14, 15)

The method of claims 14-15, wherein subject having a non-functional ATAD1 gene is a subject having a portion of all of the ATAD1 gene deleted.

### Claim 17 (depends on 15, 16)

The method of claims 15-16, wherein subject having a non-functional PTEN gene is a subject having a portion of all of the PTEN gene deleted.

### Claim 18

The method of any of the preceding claims, wherein the subject has cancer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject has breast cancer, lung cancer, colon cancer, brain cancer, or prostate cancer.

### Claim 20

The method of any of the preceding claims, wherein the proteasome inhibitor is bortezomib, ixazomib or carfilzomib.

### Claim 21

A method of comprising the steps in the following order:
(a) obtaining a sample from a cancer patient;
(b) determining whether the subject has a non-functional ATAD1 gene in the sample;
(c) identifying the cancer patient as a suitable candidate for treatment with a proteasome inhibitor if the subject has a non-functional ATAD1 gene; and
(d) administering a proteasome inhibitor to the cancer patient identified as the suitable candidate, and not administering a proteasome inhibitor to the cancer patient if the cancer patient does not have a non-functional ATAD1 gene.

### Claim 22

A method of enhancing the efficacy of a proteasome inhibitor in a subject with cancer, the method comprising administering to the subject an effective amount of a proteasome inhibitor to a subject with a non-functional ATAD1 gene.
